Gilead Sciences, Inc. (GILD) Stock Rating Reaffirmed by Maxim Group
Several other research firms have also recently weighed in on GILD. BMO Capital Markets restated an outperform rating and set a $82.00 price target (up from $72.00) on shares of Gilead Sciences in a report on Thursday, July 27th. Zacks Investment Research cut Gilead Sciences from a buy rating to a hold rating in a report on Tuesday, July 18th. BidaskClub upgraded Gilead Sciences from a sell rating to a hold rating in a report on Monday, July 24th. J P Morgan Chase & Co restated an overweight rating and set a $82.00 price target on shares of Gilead Sciences in a report on Tuesday, July 4th. Finally, Vetr cut Gilead Sciences from a strong-buy rating to a buy rating and set a $74.34 price target on the stock. in a report on Thursday, May 11th. Eleven research analysts have rated the stock with a hold rating and twenty have issued a buy rating to the company’s stock. Gilead Sciences has an average rating of Buy and a consensus target price of $82.09.
Gilead Sciences (GILD) opened at 83.71 on Monday. The firm has a market capitalization of $109.32 billion, a P/E ratio of 9.09 and a beta of 1.21. Gilead Sciences has a 52-week low of $63.76 and a 52-week high of $84.13. The firm’s 50-day moving average is $74.02 and its 200-day moving average is $69.18.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The firm had revenue of $7.14 billion for the quarter, compared to analysts’ expectations of $6.35 billion. During the same quarter in the previous year, the business posted $3.08 earnings per share. The business’s revenue for the quarter was down 8.2% on a year-over-year basis. On average, equities analysts expect that Gilead Sciences will post $8.73 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This piece was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/09/01/gilead-sciences-inc-gild-stock-rating-reaffirmed-by-maxim-group.html.
The business also recently declared a quarterly dividend, which will be paid on Thursday, September 28th. Investors of record on Friday, September 15th will be given a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.48%. The ex-dividend date is Thursday, September 14th. Gilead Sciences’s payout ratio is currently 22.58%.
In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $71.00, for a total value of $5,206,643.00. Following the completion of the transaction, the insider now owns 3,199,969 shares in the company, valued at approximately $227,197,799. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $75.88, for a total value of $1,138,200.00. Following the completion of the transaction, the executive vice president now owns 106,113 shares of the company’s stock, valued at approximately $8,051,854.44. The disclosure for this sale can be found here. Insiders sold a total of 206,666 shares of company stock valued at $15,223,184 over the last three months. 1.30% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. increased its position in shares of Gilead Sciences by 1.9% in the second quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock worth $7,425,281,000 after buying an additional 1,937,031 shares during the period. Vanguard Group Inc. increased its position in shares of Gilead Sciences by 2.4% in the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after buying an additional 2,148,697 shares during the period. Bank of New York Mellon Corp increased its position in shares of Gilead Sciences by 1.0% in the second quarter. Bank of New York Mellon Corp now owns 30,881,405 shares of the biopharmaceutical company’s stock worth $2,185,784,000 after buying an additional 310,607 shares during the period. FMR LLC increased its position in shares of Gilead Sciences by 1.1% in the second quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock worth $1,630,581,000 after buying an additional 258,005 shares during the period. Finally, Parnassus Investments CA increased its position in shares of Gilead Sciences by 37.4% in the first quarter. Parnassus Investments CA now owns 16,726,150 shares of the biopharmaceutical company’s stock worth $1,110,228,000 after buying an additional 4,556,901 shares during the period. Hedge funds and other institutional investors own 74.04% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.